Ipsen

Ipsen Interest Coverage

The Interest Coverage Ratio of Ipsen (IPN.PA) as of Sep 27, 2026 is 93.29. In the previous year, Interest Coverage Ratio was 27.29 — a change of 241.82% (higher).

Interest Coverage

93.29

YoY

241.82%

Last updated:

Interest Coverage Ratio of Ipsen is 2026 93.29 . Interest Coverage Ratio of Ipsen was 2025 27.29 . It decreases by 241.82% higher compared to the previous year.

The Ipsen Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2018
62.39 EUR
Jan 1, 2019
21.53 EUR
Jan 1, 2020
57.94 EUR
Jan 1, 2021
39.04 EUR
Jan 1, 2022
101.47 EUR
Jan 1, 2023
42.06 EUR
Jan 1, 2024
27.29 EUR
Jan 1, 2025
93.29 EUR
The Ipsen Interest Coverage history
YEARInterest CoverageYoY
93.29+241.82%
27.29-35.12%
42.06-58.55%
101.47+159.92%
39.04-32.62%
57.94+169.14%
21.53-65.50%
62.39+44.92%
43.05-18.39%
52.76-0.74%
53.15+211.03%
17.09—
Access this data via the Eulerpool API

Ipsen Stock analysis

What does Ipsen do? Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ipsen stock

Interest Coverage Ratio of Ipsen is 93.29 in 2026.

Interest Coverage Ratio of Ipsen changed from 27.29 to 93.29, representing a 241.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Ipsen since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Ipsen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Ipsen

All Key Metrics — Ipsen